Exclusive: How these drug companies won FDA priority review vouchers

Five companies actively applied, while the other four were surprised to learn they were selected after being nominated

Log In    Subscribe BREAKING NEWS   How the first nine drug companies won priority review vouchers from Marty Makary's FDA By Lizzy Lawrence Adobe Last week, the FDA announced the first recipients of the agency's new priority review voucher program, which promises winners a one- to two-month review of their drug applications, and speedy reviewer feedback.   STAT spoke with the nine voucher recipients to learn more about their therapies and how they secured vouchers. Five companies actively applied, while the other four were surprised to learn they were selected after being nominated by reviewers inside the agency.  READ MORE Sign up for Biotech Scorecard Unfiltered, uncompromising analysis on the biotech world. Learn more. In Case You Missed It Trump's IVF deal spurs hopes — and adjustments — across fertility sector By Daniel Payne Merck rolls out some showstoppers at a major cancer conference. Its future may depend on them By Andrew Joseph Exclusive: Inside FDA, career staffers describe how political pressure is influencing their work By Lizzy Lawrence CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies By Ed Silverman Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us